First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Daraxonrasib scores a plenary session late-breaker.
IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.
BeOne's degrader BG-60366 appears to have been discontinued.
The IDO/PD-L1 project mRNA-4359 shows early hints in first-line melanoma.
The disclosure comes as another of Arcus's TIGIT trials flops.
Amgen and Gilead deliver lacklustre early clinical results with AMG 355 and denikitug respectively.
